Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies

Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia, Waldenstrom 's macroglobulinemia and ma… (Source: Drug Development Technology)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uKsNAk
via IFTTT